AMRI has announced positive results from a Phase I clinical study of its MCH1 receptor antagonist, ALB-127158(a), used to treat obesity.

The placebo-controlled study evaluated the safety, tolerability and efficacy of ALB-127158(a) in male volunteers.

The drug was found to be well tolerated in both the single ascending-dose arm and the 14-day ascending-dose arm.

The common adverse event reported in both arms was loss of appetite.